Johnson & Johnson beats by $0.04, beats on revs; guides FY14 EPS towards the low end of expectations
Reports Q4 (Dec) earnings of $1.24 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus Estimate of $1.20; revenues rose 4.5% year/year to $18.36 bln vs the $17.96 bln consensus. Operational results increased 6.3% and the negative impact of currency was 1.8%. Domestic sales increased 7.4%, while international sales increased 2.4%, reflecting operational growth of 5.6% and a negative currency impact of 3.2%.
Co issues guidance for FY14, sees EPS of $5.75-5.85 vs. $5.85 Capital IQ Consensus.
"Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business, the strength of key brands in our US OTC and other Consumer businesses and continued progress in integrating Synthes into our Medical Devices and Diagnostics business. We also advanced our longer term growth drivers, bringing innovative solutions to the global healthcare market and executing with excellence."
Co issues guidance for FY14, sees EPS of $5.75-5.85 vs. $5.85 Capital IQ Consensus.
"Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business, the strength of key brands in our US OTC and other Consumer businesses and continued progress in integrating Synthes into our Medical Devices and Diagnostics business. We also advanced our longer term growth drivers, bringing innovative solutions to the global healthcare market and executing with excellence."